Current News

Contact | Print version | PDF version | Send article | RSS feed

Roche and ACEA enter exclusive world-wide agreement
Roche Applied Science acquires innovative key technology for cell-analysis

19 Nov 2007 - Roche and ACEA Biosciences Inc. announced that they have entered into an exclusive agreement for the development, supply and distribution for ACEA Bioscience's real-time cell assay technology. Under the terms of the agreement, RAS will exclusively market systems for real-time cell analysis, based on ACEA Bioscience's impedance-based technology. This technology is designed for a multitude of applications spanning from short term kinetic analysis, for example for measuring effects on G-protein coupled receptors (GPCRs), to assays for cell proliferation, cytotoxicity, and even cell migration and invasion.
 
Financial terms of the contract were not disclosed.
 
"After completing our product portfolio in DNA/RNA analysis with 454 and NimbleGen, the ACEA technology will be an essential cornerstone to strengthen and further extend our product portfolio in cell analysis. We are convinced that ACEA´s platform products for cell based assays will form a new industrial standard for life science cell-analysis," commented Manfred Baier, Head of Roche Applied Science.